---
title: Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults
nct_id: NCT03945903
overall_status: NO_LONGER_AVAILABLE
sponsor: Janssen Research & Development, LLC
study_type: EXPANDED_ACCESS
primary_condition: Diabetes Mellitus, Type 1
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03945903.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03945903"
ct_last_update_post_date: 2023-04-13
last_seen_at: "2026-05-12T07:02:12.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults

**Official Title:** SIMPONI SC Managed Access Program

**NCT ID:** [NCT03945903](https://clinicaltrials.gov/study/NCT03945903)

## Key Facts

- **Status:** NO_LONGER_AVAILABLE
- **Study Type:** EXPANDED_ACCESS
- **Lead Sponsor:** Janssen Research & Development, LLC
- **Conditions:** Diabetes Mellitus, Type 1
- **CT.gov Last Update:** 2023-04-13

## Brief Summary

This is a Single Patient Investigational New Drug (IND) to golimumab subcutaneous (SC) for the treatment of recently diagnosed Stage 3 type-1 diabetes mellitus (T1D) in children and young adults. The main purpose of a single patient IND is to provide treatment to participants with serious/life-threatening diseases or conditions prior to marketing authorization.

## Eligibility

```
Inclusion Criteria:

\-

Exclusion Criteria:

\-
```

## Interventions

- **Golimumab** (DRUG) — Participants will receive subcutaneous (SC) golimumab, where doses will be based on weight and/or body surface area.

## Locations (1)

- Rady Children's Hospital, San Diego, California, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.rady children's hospital|san diego|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03945903.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03945903*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*